A new standard of
care in SFA stenting.
BOLD CLINICAL TRIALS
One DES head-to-head trial.
Built for sustained drug release and efficient drug transfer.
EMINENT Randomized Controlled Trial Results3
Eluvia DES demonstrated superior primary patency4 over bare metal stents through 1-Year in the world's largest RCT of SFA stents.
**Log-rank p-value compares the entire K-M curves from time point zero to day 395 (full 1-year follow-up window)
1. 92.1% K-M Primary Patency. Gray W. 2-year Outcomes from the IMPERIAL Randomized Head to Head Study of Eluvia DES and Zilver PTX; LINC 2020, Leipzig Jan 28,2020.
2. Drug Dose Data from Eluvia DES, Zilver PTX, Lutonix 018 DCB, Lutonix 035 DCB, Stellarex 035 DCB and Ranger DCB Instructions for Use. Data on file at Boston Scientific. Represents total global sales of the PROMUS (Boston Scientific) and XIENCE (Abbott) stents since 2006.
3. EMINENT RCT 1-Year results presented by Yann Gouëffic, MD. VIVA 2021.
4. EMINENT Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against commercially-available Self-Expanding Bare Nitinol Stents, single-blind, superiority design; independent core lab adjudication. Primary Endpoint: 1-Year Binary Primary Patency rate of 83.2% in the Eluvia arm vs. 74.3% in the Bare-Metal Stenting arm (p-value = 0.0077).
RESTENOSIS REPLACEMENT PROGRAM
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.